Brett Guthrie will expand access to innovative, lifesaving treatments for vulnerable Americans with rare diseases by advancing the Medicaid VBPs for Patients Act and value-based Medicaid purchasing agreements.

I'm pleased to reintroduce my bipartisan MVP Act to expand access to innovative, lifesaving treatments for vulnerable Americans with rare diseases. This transformative legislation would give states the flexibility to offer high-cost therapies for rare diseases without raising taxes or cutting other state programs.

Guthrie said he reintroduced the bipartisan MVP Act to expand access to lifesaving rare-disease treatments and give states flexibility to offer high-cost therapies through value-based Medicaid payment arrangements.

Chairman Brett Guthrie Reintroduces Bipartisan Legislation to Expand Access to Treatment for Rare Diseases | U.S. Congressman Brett Guthrie
primary · press_release · model gpt-5.5

CMS finalized a rule to support state flexibility to enter value-based purchasing arrangements with manufacturers, including Medicaid, effective March 1, 2021 with some provisions effective January 1, 2022.

The Medicaid VBP policy framework exists through CMS rulemaking before the relevant 119th Congress period, not through a Guthrie-sponsored Medicaid VBPs for Patients Act.

partial unknown

Federal Register: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review and Supporting Value-Based Purchasing for Drugs Covered in Medicaid
secondary · model gpt-5.5 · confidence 84%

Current regulation defines a value-based purchasing arrangement as one intended to align pricing or payments to observed or expected therapeutic or clinical value, including evidence-based or outcomes-based measures.

Current Medicaid drug rebate regulations include a VBP definition, showing the underlying policy mechanism is active but not proving Guthrie enacted or advanced the named Act.

partial unknown

eCFR: 42 CFR 447.502 Definitions
secondary · model gpt-5.5 · confidence 82%

Current regulation states that if a manufacturer offers a VBP arrangement to all states, best price may include varying best price points for a single dosage form and strength because of that arrangement.

CMS regulations allow Medicaid best-price treatment for value-based purchasing arrangements, but this is regulatory delivery rather than evidence that Guthrie fulfilled the promise through the Medicaid VBPs for Patients Act.

partial unknown

eCFR: 42 CFR 447.505 Determination of best price
secondary · model gpt-5.5 · confidence 82%

Congress.gov lists Brett Guthrie as Representative for Kentucky District 2 in the 111th-119th Congresses and shows his sponsored legislation and member activity records.

The official member record confirms the relevant federal office and legislative activity source, but searches did not identify a Medicaid VBPs for Patients Act sponsored or enacted by Guthrie as of July 1, 2026.

never same_term

Brett Guthrie | Congress.gov | Library of Congress
secondary · model gpt-5.5 · confidence 68%

H.R.1 became Public Law 119-21 on July 4, 2025. Its health title includes extensive Medicaid provisions such as eligibility redeterminations, provider tax limits, work requirements, cost sharing, HCBS waivers, and rural health funding; the page contains no matching text for value-based purchasing.

The major 119th Congress Medicaid law did not deliver the promised Medicaid VBP rare-disease treatment policy, though it did contain other Medicaid and orphan-drug provisions.

never same_term

Congress.gov: H.R.1, 119th Congress, Public Law 119-21
secondary · model gpt-5.5 · confidence 76%

The House vote on concurring in the Senate amendment to H.R.1 passed 218-214. Brett Guthrie, Republican of Kentucky, voted Aye.

Guthrie supported the major Medicaid-containing reconciliation law, but that vote does not show advancement of the Medicaid VBPs for Patients Act or value-based Medicaid purchasing agreements for rare diseases.

never same_term

Office of the Clerk: Roll Call 190, H.R.1, 119th Congress
secondary · model gpt-5.5 · confidence 74%